An Expert Guide to What’s New and What’s Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma

Review the latest clinical trial data on approved and emerging targeted therapies for the management of relapsed/refractory follicular lymphoma with downloadable slides and an archived webcast from a live, expert-led symposium at ASH 2023, along with a companion FAQ commentary where experts answer audience questions from the live program.

Share

Program Content

Activities

CAR T-Cell Tx in R/R FL
CAR T-Cell Therapy in the Management of Relapsed/Refractory Follicular Lymphoma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2023

Bispecific Antibodies in R/R FL
Bispecific Antibodies in the Management of Relapsed/Refractory Follicular Lymphoma
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2023

FL Tx Landscape and EZH2i in R/R FL
Follicular Lymphoma Treatment Landscape and EZH2 Inhibition in Relapsed/Refractory Disease
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2023

Activities

Expert guide on RR FL
Expert Guide: What’s New and Next for Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma
Video
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2023

Expires: December 18, 2024

Activities

3L+ RR FL FAQs
Novel Targeted Therapies in Relapsed/Refractory Follicular Lymphoma: Experts Answer Frequently Asked Questions
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: January 29, 2024

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Genentech, a member of the Roche Group; Genmab; Ipsen Biopharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc.

Genentech, a member of the Roche Group

Genmab

Ipsen Biopharmaceuticals Inc

Regeneron Pharmaceuticals, Inc